Genetic Pathology Evaluation Centre

TMA Images

David Huntsman

Associate Professor - University of British Columbia, Faculty of Medicine - since 2005
Genetic Pathologist - British Columbia Cancer Agency, Department of Pathology and Laboratory Medicine - since 1999
Research Affiliate - Vancouver General Hospital, The Prostate Research Centre - since 2000
Director - DNA Diagnostic Laboratory, British Columbia Children’s Hospital - 1999-2000
Honorary Visiting Fellow - University of Cambridge, UK - 1997-1999

POST-SECONDARY EDUCATION

MD - Memorial University Newfoundland, Canada (1984-1988)

SPECIAL PROFESSIONAL QUALIFICATIONS

Clinical Oncology/Cancer Genetics - University of Cambridge, UK (1997-1999)
FCCMG Clinical Molecular Genetics - Canadian College of Medical Genetics, Canada (1995-1997)
FRCPC General Pathology - Royal College of Physicians and Surgeons, Canada (1991-1995)
Anatomic and Clinic Pathology Boards - American Pathology Boards, USA (1991-1995)
LMCC - Medical Council of Canada (1991)

COMMITTEE MEMBERSHIPS

Ontario Institute for Cancer Research, Genomics/Bioinformatics Advisory Panel, March 2009 -
VCHRI - In It For Life, Clinical Investigator Award Search Committee, November 2008 -
Marsha Rivkin Center, Think Tank Steering Committee, November 2008 -
Hereditary Diffuse Gastric Cancer Cambridge Workshop Organizing Committee, 2008
Canadian Cancer Research Alliance/International Cancer Genome Consortium Strategic Planning Subcommittee, 2008 - present
Ovarian Cancer Canada, Grants Review Panel, 2008 - present
Marsha Rivkin Center, Scientific Advisory Board Member, 2008 - present
National Cancer Institute, Panel J2 Chair, 2008 - present
Terry Fox Research Institute Advisory Committee, 2006 - present
The Cancer Genome Atlas, Ovarian Cancer Working Group Member, 2007 - present
BC Proteomics Network Organizing Committee, 2007
BCCRC Noon Seminar Series Committee, 2007 - present
BCCRC Awards, Scholarships, Bursaries Committee, 2007 - present
USCAP Education Committee, 2005 - present
MSFHR Research Advisory Council, 2005 - present
Canadian Medical Association, 2005 - present
BCCA Gynecology Executive Committee, 2005 - present
Diagnostic Accreditation Program, 2005
Ontario Cancer Research Network, 2005
National Cancer Institute of Canada, Panel J
MSFHR Scientific Advisory Committee, 2004 - present
MSFHR Clinical Trainee Evaluation Committee, 2003 - 2006
Diagnostic Accreditation Program: Molecular Pathology Group, 2000 - present
BCIT Advisory Committee for the Genetic Technology Training Program, Chair, 2000 - 2002
BCCA Hereditary Cancer program Steering Committee, 1999 - present
BC Diagnostic Accreditation Molecular Pathology Working Group, 1999 - present
BCCA Guidelines and Protocols Committee (Hemochromatosis), 1999 - present
BCMA Protocols and Guidelines Committee (Hemochromatosis), 1999 - 2001
Member of Panel J Review Committee National Cancer Institute of Canada

AWARDS AND DISTINCTIONS

Vancouver General Hospital - Scientific Achievement Award (2005)
Marsha Rivkin Centre Scientific Scholar Award (2004)
Medical Advisory Council - Scientific Achievement Award (2004)
Canadian Society for Clinical Investigation: Joe Doupe Young Investigator's Award (2004)
Research and Discovery Award, Pathology Day, UBC (2003)
Michael Smith Career Investigator Award - Michael Smith Foundation (2002)
Benjamin Castleman Award, United States and Canadian Academy of Pathology and Society for Pediatric Pathology, Chicago (2002)
VP Research: Faculty Development Award - BCCA: Simon Sutcliffe (2001)
Translational Research Award - Start up funds - UBC Department of Pathology (2001)
VP Research: Faculty Development Award - UBC: VP Research (2001)
McLaughlin Fellowship $45,000 x 2 years - UBC (1997)
Resident Research Award - UBC (1994)
Residents Research Prize - MRC of Canada, Canadian Society of Clinical Researchers (1994)
Pathology Prize 1986 for best marks in the first and second year pathology courses - Memorial University of Newfoundland (1986)
Newfoundland Medical Association Scholarship 1986 for scholastic excellence and community involvement - Memorial University of Newfoundland (1986)

SELECTED PUBLICATIONS
Journals

Madore J, Ren F, Filali-Mouhim A, Sanchez L, Köbel M, Tonin PN, Huntsman D, Provencher DM, Mes-Masson AM. (2010-02-01). Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol. 220(3),392
Gökmen-Polar Y, Mehta R, Tuzmen S, Mousses S, Thorat MA, Sanders KL, Turbin D, Leung S, Huntsman DG, Sledge GW Jr, Badve S. (2010-01-23). Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes. Breast Cancer Res Treat. 0(0),0
Sun Y, Turbin D, Ling K, Thapa N, Leung S, Huntsman D, Anderson RA. (2010-01-14). Type I gamma phosphatidylinositol phosphate kinase modulates invasion and proliferation and its expression correlates with poor prognosis in breast cancer. Breast Cancer Res Treat. 0(0),0
Falconer E, Chavez EA, Henderson A, Poon SS, McKinney S, Brown L, Huntsman DG, Lansdorp PM. (2010-01-07). Identification of sister chromatids by DNA template strand sequences. Nature. 463(7277),93
Köbel M, Gilks CB, Huntsman DG. (2009-12-15). Adult-type granulosa cell tumors and FOXL2 mutation. Cancer Res. 69(24),9160
McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Köbel M, Kalloger SE, Swenerton KD, Huntsman DG, Gilks CB, Miller DM. (2009-12-10). HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer. 9(0),433
Schrader KA, Gorbatcheva B, Senz J, Heravi-Moussavi A, Melnyk N, Salamanca C, Maines-Bandiera S, Cooke SL, Leung P, Brenton JD, Gilks CB, Monahan J, Huntsman DG. (2009-11-24). The Specificity of the FOXL2 c.402C>G Somatic Mutation: A Survey of Solid Tumors. PLoS One. 4(11),7988
Aparicio SA, Huntsman DG. (2009-11-17). Does massively parallel DNA resequencing signify the end of histopathology as we know it? J Pathol. 220(2),307
Watson PH, Wilson-McManus JE, Barnes RO, Giesz SC, Png A, Hegele RG, Brinkman JN, Mackenzie IR, Huntsman DG, Junker A, Gilks B, Skarsgard E, Burgess M, Aparicio S, McManus BM. (2009-11-12). Evolutionary concepts in biobanking - the BC BioLibrary. J Transl Med. 7(0),95
Bocanegra M, Bergamaschi A, Kim YH, Miller MA, Rajput AB, Kao J, Langerød A, Han W, Noh DY, Jeffrey SS, Huntsman DG, Børresen-Dale AL, Pollack JR. (2009-11-02). Focal amplification and oncogene dependency of GAB2 in breast cancer. Oncogene. 0(0),0
Köbel M, Kalloger SE, Santos JL, Huntsman DG, Gilks CB, Swenerton KD. (2009-10-10). Tumor type and substage predict survival in stage I and II ovarian carcinoma: Insights and implications. Gynecol Oncol. 116(1),50
Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J, Steidl C, Holt RA, Jones S, Sun M, Leung G, Moore R, Severson T, Taylor GA, Teschendorff AE, Tse K, Turashvili G, Varhol R, Warren RL, Watson P, Zhao Y, Caldas C, Huntsman D, Hirst M, Marra MA, Aparicio S. (2009-10-08). Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature. 461(7265),809
Lee CH, Subramanian S, Beck AH, Espinosa I, Senz J, Zhu SX, Huntsman D, van de Rijn M, Gilks CB. (2009-10-02). MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One. 4(10),7314
Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L. (2009-09-20). Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol. 27(27),4536
Brown LA, Johnson K, Leung S, Bismar TA, Benítez J, Foulkes WD, Huntsman DG. (2009-07-28). Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. Breast Cancer Res Treat. 0(0),0
Shah SP, Koebel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFazio A, Khattra J, Turashvili G, Zhao Y, Zeng T, Glover JN, Vanderhyden B, Zhao C, Parkinson CA, Jimenez-Linan M, Bowtell DD, Mes-Masson AM, Brenton JD, Aparicio SA, Boyd N, Hirst M, Gilks CB, Marra M, Huntsman DG. (2009-06-10). Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 360(26),2719
Turashvili G, Leung S, Turbin D, Montgomery K, Gilks B, West R, Carrier M, Huntsman D, Aparicio S. (2009-05-29). Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis. BMC Cancer. 9(0),165
Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, Parker JS, Miller MA, Huntsman DG, Lin L, Snider J, Davies SR, Olson JA Jr, Watson MA, Saporita A, Weber JD, Ellis MJ. (2009-04-14). PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res. 69(9),3955
KÃ¶bel M, Gilks CB, Huntsman DG. (2009-03-12). Dicer and Drosha in ovarian cancer. N Engl J Med. 360(11),1150
Salvador S, Gilks B, KÃ¶bel M, Huntsman D, Rosen B, Miller D. (2009-02-01). The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer. 19(1),58
KÃ¶bel M, Xu H, Bourne PA, Spaulding BO, Shih IM, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, Lee CH, Huntsman D, Gilks CB. (2009-01-09). IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol. 22(3),469
KÃ¶bel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, Ewanowich CA, Soslow RA, Gilks CB. (2009-01-01). A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary. Am J Surg Pathol. 33(1),14
Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, Kalloger S, Han G, Ceballos K, Cadungog MG, Huntsman DG, Coukos G, Gilks CB. (2008-12-05). Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 22(3),393
KÃ¶bel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D. (2008-12-02). Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 5(12),232
Thorat MA, Turbin D, Morimiya A, Leung S, Zhang Q, Jeng MH, Huntsman DG, Nakshatri H, Badve S. (2008-12-01). Amplified in breast cancer 1 expression in breast cancer. Histopathology 53(6),634
Schrader KA, Nelson TN, De Luca A, Huntsman DG, McGillivray BC. (2008-11-27). Multiple granular cell tumors are an associated feature of LEOPARD syndrome caused by mutation in PTPN11. Clin Genet. 75(2),185
Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO, Gelmon K. (2008-11-10). Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers. J Clin Oncol. 26(35),5697
Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE. (2008-10-16). Re-defining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res. 10(5),86
Bergamaschi A, Kim YH, Kwei KA, La Choi Y, Bocanegra M, LangerÃ¸d A, Han W, Noh DY, Huntsman DG, Jeffrey SS, BÃ¸rresen-Dale AL, Pollack JR. (2008-10-02). CAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancer. Mol Oncol. 2(4),327
Wong MP, Cheang M, Yorida E, Coldman A, Gilks CB, Huntsman D, Berean K. (2008-10-01). Loss of desmoglein 1 expression associated with worse prognosis in head and neck squamous cell carcinoma patients. Pathology. 40(6),611
Giltnane JM, Molinaro A, Cheng H, Robinson A, Turbin D, Gelmon K, Huntsman D, Rimm DL. (2008-10-01). Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer. Arch Pathol Lab Med. 132(10),1635
Salvador S, Rempel A, Soslow RA, Gilks B, Huntsman D, Miller D. (2008-09-01). Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol. 110(3),408
Weichert W, Denkert C, Noske A, Darb-Esfahani S, Dietel M, Kalloger SE, Huntsman DG, KÃ¶bel M. (2008-09-01). Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia. 10(9),1021
FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, Fazli L, Rajput AB, Gleave ME, Cox ME, Ostrander EA, Stanford JL, Huntsman DG. (2008-08-11). Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer. 8(0),230
KÃ¶bel M, Huntsman D, Gilks CB. (2008-08-01). Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev Mol Med. 22(0),10
Miller MA, Huntsman DG, Lapointe J, Pollack JR. (2008-08-01). Reply to perner and rubin. Mod Pathol. 21(8),1056
Brown LA, Hoog J, Chin SF, Tao Y, Zayed AA, Chin K, Teschendorff AE, Quackenbush JF, Marioni JC, Leung S, Perou CM, Neilsen TO, Ellis M, Gray JW, Bernard PS, Huntsman DG, Caldas C. (2008-07-01). ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet. 40(7),806
Press JZ, Kenyon JA, Xue H, Miller MA, De Luca A, Miller DM, Huntsman DG, Gilks CB, McAlpine JN, Wang YZ. (2008-06-10). Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol Oncol. 110(2),256
Brown LA, Kalloger SE, Miller MA, Shih IeM, McKinney SE, Santos JL, Swenerton K, Spellman PT, Gray J, Gilks CB, Huntsman DG. (2008-06-01). Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer. 47(6),481
Crabb SJ, Cheang MC, Leung S, Immonen T, Nielsen TO, Huntsman DD, Bajdik CD, Chia SK. (2008-06-01). Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer. 8(3),249
Woo MM, Salamanca CM, Miller M, Symowicz J, Leung PC, Oliveira C, Ehlen TG, Gilks CB, Huntsman D, Auersperg N. (2008-01-23). Serous borderline ovarian tumors in long-term culture: phenotypic and genotypic distinction from invasive ovarian carcinomas. Int J Gynecol Cancer. 18(6),1234
Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA, Smith M, Spellman PT, Wang Y, Miller DM, Horsman D, Faham M, Gilks CB, Gray J, Huntsman DG. (2008-01-22). Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer. 8(17),0
Crabb SJ, Bajdik CD, Leung S, Speers CH, Kennecke H, Huntsman DG, Gelmon KA. (2008-01-14). Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study. Breast Cancer Res. 10(1),6
Jensen KC, Turbin DA, Leung S, Miller MA, Johnson K, Norris B, Hastie T, McKinney S, Nielsen TO, Huntsman DG, Gilks CB, West RB. (2008-01-09). New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up. Breast Cancer Res Treat. 112(3),453
Fadlelmola FM, Zhou M, de Leeuw RJ, Dosanjh NS, Harmer K, Huntsman D, Lam WL, Banerjee D. (2008-01-07). Sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization profiling reveals novel gains and losses of chromosomal regions in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma cell lines. Mol Cancer. 7(2),0
Edwards LA, Woo J, Huxham LA, Verreault M, Dragowska WH, Chiu G, Rajput A, Kyle AH, Kalra J, Yapp D, Yan H, Minchinton AI, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S, Bally MB. (2008-01-01). Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of Integrin-linked kinase (ILK). Mol Cancer Ther. 7(1),59
Pinke DE, Kalloger SE, Francetic T, Huntsman DG, Lee JM. (2007-12-28). The prognostic significance of elongation factor eEF1A2 in ovarian cancer. Gynecol Oncol. 108(3),561
Hewitt J, Craven SJ, Brown LA, Bleackley MR, Ballard JN, Smith VC, Ofosu FA, Huntsman DG, Wadsworth LD, Wu JK, Macgillivray RT. (2007-12-19). Molecular determination of the breakpoints of a 161 556 bp deletion at chromosome 13q34 that presented as severe factor VII deficiency in a neonate. Br J Haematol. 140(5),589
Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL. (2007-12-01). Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its ... J Clin Oncol. 25(34),5418
Bajdik CD, Sung S, Spinelli JJ, Huntsman D, Gallinger S, Horsman D, Gallagher RP. (2007-12-01). Predicting the performance of a genetic testing service for cancer susceptibility. Genet Test. 11(4),381
Intaraprasong P, Assi K, Owen DA, Huntsman DG, Chung SW, Scudamore CH, Yoshida EM, Salh B. (2007-12-01). Expression of integrin-linked kinase is not a useful prognostic marker in resected hepatocellular cancer. Anticancer Res. 27(6),4371
Prentice LM, Klausen C, Kalloger S, Kobel M, McKinney S, Santos JL, Kenney C, Mehl E, Gilks CB, Leung P, Swenerton K, Huntsman DG, Aparicio SA. (2007-11-15). Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. BMC Med. 5(1),33
Turbin DA, Leung S, Cheang MC, Kennecke HA, Montgomery KD, McKinney S, Treaba DO, Boyd N, Goldstein LC, Badve S, Gown AM, van de Rijn M, Nielsen TO, Gilks CB, Huntsman DG. (2007-10-03). Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res Treat. 110(3),417
Savage K, Leung S, Todd SK, Brown LA, Jones RL, Robertson D, James M, Parry S, Rodrigues Pinilla SM, Huntsman D, Reis-Filho JS. (2007-10-03). Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res Treat. 110(2),245
Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL, Kalloger SE, Carlson JW, Ginzinger DG, Celniker SE, Mills GB, Huntsman DG, Gray JW. (2007-10-01). Amplification of PVT1 Contributes to the Pathophysiology of Ovarian and Breast Cancer. Clin Cancer Res. 13(19),5745
Alkushi A, Clarke BA, Akbari M, Makretsov N, Lim P, Miller D, Magliocco A, Coldman A, van de Rijn M, Huntsman D, Parker R, Gilks CB. (2007-08-24). Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod Pathol. 20(11),1156
Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H. (2007-08-01). FOXA1 Expression in Breast Cancer Correlation with Luminal Subtype A and Survival. Clin Cancer Res. 13(15),4415
Masciari S, Larsson N, Senz J, Boyd N, Kaurah P, Kandel MJ, Harris LN, Pinheiro HC, Troussard A, Miron P, Tung N, Oliveira C, Collins L, Schnitt S, Garber JE, Huntsman D. (2007-07-27). Germline E-Cadherin mutations in familial lobular breast cancer. J Med Genet. 44(11),726
Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD. (2007-07-24). Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 7(1),134
Ursini-Siegel J, Rajput AB, Lu H, Sanguin-Gendreau V, Zuo D, Papavasiliou V, Lavoie C, Turpin J, Cianflone K, Huntsman DG, Muller WJ. (2007-07-16). Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development. Mol Cell Biol. 27(18),6361
Conklin C, Huntsman D, Yorida E, Makretsov N, Turbin D, Bechberger JF, Sin WC, Naus CC. (2007-06-20). Tissue microarray analysis of connexin expression and its prognostic significance in human breast cancer. Cancer Lett. 255(2),284
Cupp JS, Miller MA, Montgomery KD, Nielsen TO, Oʼconnell JX, Huntsman D, Rijn MV, Gilks CB, West RB. (2007-06-01). Translocation and Expression of CSF1 in Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor, Rheumatoid Arthritis and Other Reactive Synovitides. Am J Surg Pathol. 31(6),970
Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, Gilks CB, Huntsman DG. (2007-03-13). Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat. 107(2),249
Lapointe J, Kim YH, Miller MA, Li C, Kaygusuz G, van de Rijn M, Huntsman DG, Brooks JD, Pollack JR. (2007-03-02). A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol. 20(4),467
Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D, Gilks B. (2007-02-01). Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol. 14(2),719
Ling K, Bairstow SF, Carbonara C, Turbin DA, Huntsman DG, Anderson RA. (2007-01-29). Type I{gamma} phosphatidylinositol phosphate kinase modulates adherens junction and E-cadherin trafficking via a direct interaction with {micro}1B adaptin. J Cell Biol. 176(3),343
Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, Fazli L, Jones EC, Palmer JB, Gleave ME, Cox ME, Huntsman DG. (2007-01-26). Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol. 60(11),1238
Brown LA, Huntsman D. (2007-01-10). Fluorescent in situ hybridization on tissue microarrays: challenges and solutions. J Mol Histol. 38(2),151
Cheang MC, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, Goldstein LC, Gelmon KA, Huntsman D, Gilks CB, Nielsen TO, Gown AM. (2006-12-20). Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival. J Clin Oncol. 24(36),5637
Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG. (2006-11-24). Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol. 20(1),84
Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Zhang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB. (2006-09-01). Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Curr Cancer Drug Targets. 6(6),455
Kulkarni G, Turbin DA, Amiri A, Jeganathan S, Andrade-Navarro MA, Wu TD, Huntsman DG, Lee JM. (2006-08-09). Expression of protein elongation factor eEF1A2 predicts favorable outcome in breast cancer. Breast Cancer Res Treat. 102(1),31
Robinson AG, Turbin D, Thomson T, Yorida E, Ellard S, Bajdik C, Huntsman D, Gelmon K. (2006-08-01). Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease. Clin Breast Cancer. 7(3),254
Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Filipenko D, Huntsman D, Gilks B. (2006-05-01). Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg. 191(5),581
Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, Ellis IO, Huntsman D, Caldas C. (2006-04-15). Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index Clin Cancer Res. 12(8),2468
West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, Zhu S, Marinelli RJ, De Luca A, Downs-Kelly E, Goldblum JR, Corless CL, Brown PO, Gilks CB, Nielsen TO, Huntsman D, van de Rijn M. (2006-01-17). A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A 103(3),690
Turbin DA, Cheang MC, Bajdik CD, Gelmon KA, Yorida E, De Luca A, Nielsen TO, Huntsman DG, Gilks CB. (2006-01-01). MDM2 protein expression is a negative prognostic marker in breast carcinoma. Modern Pathology 19(1),69
So A, Sinnemann S, Huntsman D, Fazli L, Gleave M. (2005-12-01). Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol Cancer Ther. 4(12),1837
Honrado E, Osorio A, Palacios J, Milne RL, Sanchez L, Diez O, Cazorla A, Syrjakoski K, Huntsman D, Heikkila P, Lerma E, Kallioniemi A, Rivas C, Foulkes WD, Nevanlinna H, Benitez J. (2005-10-20). Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J Clin Oncol. 23(30),7503
Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, Chia S, Magliocco A, Makretsov N, Gilks B, Pollack J, Huntsman D. (2005-10-19). Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecologic Oncology 100(2),264
Feng Q, Li P, Salamanca C, Huntsman D, Leung PC, Auersperg N. (2005-10-01). Caspase-1alpha is down-regulated in human ovarian cancer cells and the overexpression of caspase-1alpha induces apoptosis. Cancer Res. 65(19),8591
Raouf A, Brown L, Vrcelj N, To K, Kwok W, Huntsman D, Eaves CJ. (2005-09-07). Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY. J Natl Cancer Inst. 97(17),1302
Kucab JE, Lee C, Chen CS, Zhu J, Gilks CB, Cheang M, Huntsman D, Yorida E, Emerman J, Pollak M, Dunn SE. (2005-08-01). Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res. 7(5),796
Prentice LM, Shadeo A, Lestou VS, Miller MA, Deleeuw RJ, Makretsov N, Turbin D, Brown LA, Macpherson N, Yorida E, Cheang MC, Bentley J, Chia S, Nielsen TO, Gilks CB, Lam W, Huntsman DG. (2005-07-18). NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. Oncogene. 24(49),7281
Kelley TW, Huntsman D, McNagny KM, Roskelley CD, Hsi ED. (2005-07-01). Podocalyxin : A Marker of Blasts in Acute Leukemia Am J Clin Pathol. 124(1),134
Arce C, Cortes-Padilla D, Huntsman DG, Miller MA, Duennas-Gonzalez A, Alvarado A, Perez V, Gallardo-Rincon D, Lara-Medina F. (2005-06-17). Secretory carcinoma of the breast containing the ETV6-NTRK3 fusion gene in a male: case report and review of the literature. World J Surg Oncol. 3(1),35
Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M, Leighton Grimes H, Miller K, Badve S, Huntsman D, Blake-Gilks C, Chen M, Pallen CJ, Dunn SE. (2005-06-16). Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene. 24(26),4281
Terry J, Barry TS, Horsman DE, Hsu FD, Gown AM, Huntsman DG, Nielsen TO. (2005-06-01). Fluorescence In Situ Hybridization for the Detection of t(X;18)(p11.2;q11.2) in a Synovial Sarcoma Tissue Microarray Using a Breakapart-Style Probe. Diagn Mol Pathol. 14(2),77
Wiseman SM, Makretsov N, Nielsen TO, Gilks B, Yorida E, Cheang M, Turbin D, Gelmon K, Huntsman DG. (2005-05-01). Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer. 103(9),1770
Zhou Y, Dai DL, Martinka M, Su M, Zhang Y, Campos EI, Dorocicz I, Tang L, Huntsman D, Nelson C, Ho V, Li G. (2005-05-01). Osteopontin expression correlates with melanoma invasion. J Invest Dermatol. 124(5),1044
Lee CH, Huntsman DG, Cheang MC, Parker RL, Brown L, Hoskins P, Miller D, Gilks CB. (2005-04-01). Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol. 24(2),147
Suriano G, Vrcelj N, Senz J, Ferreira P, Masoudi H, Cox K, Nabais S, Lopes C, Machado JC, Seruca R, Carneiro F, Huntsman DG. (2005-03-01). beta-Catenin (CTNNB1) gene amplification: A new mechanism of protein overexpression in cancer. Genes, Chromosomes and Cancer 42(3),238
Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, Gilks CB, Wang YZ. (2004-10-28). Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncology 96(1),48
Au NHC, Gown A, Cheang M, Huntsman D, Yorida E, Elliott WM, Flint J, English J, Gilks CB, Grimes HL. (2004-09-01). p63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 12(3),240
Au NHC, Cheang M, Huntsman DG, Yorida E, Coldman A, Elliot WM, Bebb G, Flint J, English J, Gilks CB, Grimes HL. (2004-09-01). Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers J of Pathology (UK) 204(1),101
Somasiri A, Nielsen J, Makretsov N, Prentice L, Gilks CB, Chia SK, Gelmon KA, Kershaw DB, Huntsman DG, McNagny KM, and Roskelley CD. (2004-08-01). Overexpression of the Anti-Adhesin Podocalyxin Is an Independent Predictor of Breast Cancer Progression Cancer Research 64(15),5068
Makretsov N, Huntsman D, Nielsen T, Yorida E, Peacock M, Cheang M, Sandra E.Dunn, Hayes M, Matt van de Rijn, Bajdik C, and Gilks B. (2004-08-01). Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data Identifies Prognostically Significant Groups of Breast Cancer Clinical Cancer Research 10(18),6143
Dabiri SH, Huntsman DG, Makretsov N, Cheang M, Gilks CB, Bajdik C, Gelmon KA, Chia S, Hayes MM. (2004-06-15). The presence of stromal mast cells identifies a subset of invasive breast cancers with a favourable prognosis. Mod Pathol 17(6),690
Makretsov N, He M, Hayes M, Chia S, Horsman DE, Sorensen PH, and Huntsman D. (2004-06-01). A fluorescence in-situ hybridisation study of ETV6-NTRK3 fusion gene in secretory breast carcinoma. Genes Chromosomes Cancer 40(2),152
Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, Gilks CB. (2004-04-01). Interpretation of p53 immunohistochemical staining in endometrial carcinoma: establishing a clinically relevant cut-off. Int J Gynecol Pathol 23(2),129
Maines-Bandiera SL, Huntsman D, Lestou VS, Kuo WL, Leung PC, Horsman RD, Wong AS, Woo MM, Choi KK, Roskelley CD, Auersperg N. (2004-04-01). Epithelio-mesenchymal transition in a neoplastic ovarian epithelial hybrid cell line. Differentiation. 72(4),150
Nielsen TO, Andrews HN, Cheang M, Kucab JE, Hsu FD, Ragaz J, Gilks CB,Makretsov N, Bajdik CD, Brookes C, Neckers LM, Evdokimova V, Huntsman DG, Dunn SE (2004-01-01). Expression of the Insulin-Like Growth Factor I Receptor and Urokinase Plasminogen Activator in Breast Cancer Is Associated with Poor Survival Cancer Research 64(1),286
Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin S-F, Milner J, Brown LA, Hsu F, Gilks B, Nielsen T, Schulzer M, Chia S, Ragaz J, Cahn A, Linger L, Ozdag H, Cattaneo E, Jordanova ES, Yu DS, Vnkitaraman A, Ponder B, Doherty A, Aparicio S, (2003-11-26). EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115(5),523
Makretsov N, Gilks CB, Coldman AJ, Hayes M, and Huntsman D. (2003-10-15). Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol 34(10),1001
Dai DL, Makretsov N, Campos EI, Huang C, Zhou Y, Huntsman D, Martinka M, and Li G. (2003-10-01). Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. Clin Cancer Res 9(0),4409
Thiessen B, Maguire JA, McNeil K, Huntsman D, Martin MA, Horsman D. (2003-09-01). Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. J Neurooncol. 64(3),271
Bamforth F, Brown L, Senz J, Huntsman D. (2003-07-01). Mechanisms of monozygotic (MZ) twinning: a possible role for the cell adhesion molecule, E-cadherin. Am J Med Genet A. 120(1),59
Hsu FD, Nielsen TO, Alkushi A, Dupuis B, Huntsman D, Liu CL, van de Rijn M, Gilks CB. (2002-12-15). Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol 15(12),1374
Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, Becker L, Carneiro F, MacPherson N, Horsman D, Poremba C, Sorensen PH. (2002-11-01). Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2(5),367
Mattman A, Huntsman D, Lockitch G, Langlois S, Buskard N, Ralston D, Butterfield Y, Rodrigues P, Jones S, Porto G, Marra M, De Sousa M, Vatcher G. (2002-08-01). Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation. Blood. 100(3),1075
Parker RL, Huntsman DG, Lesack DW, Cupples JB, Grant DR, Akbari M, and Gilks CB. (2002-03-01). Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol. 117(0),723

Invited Presentations

Ontario Institute for Cancer Research and National Cancer Institute of Canada, State of the Science and Technology of Circulating Tumour Cells as Biomarkers in Cancer Treatment Trials Workshop, Toronto ON, March 28, 2009. Presentation "Detection of genetic abnormalities in CTCs".
University of Chicago Pritzker School of Medicine, Breast Cancer Family Registry: 2nd Scientific Conference on Familial Aspects of Breast Cancer, San Antonio TX, December 10, 2008. Presentation "The role of CDH1 in breast cancer susceptibility"
London Regional Cancer Program Translational Breast Cancer Research Unit and the CIHR Strategic Training Program in Cancer Research and Technology Transfer - CIHR Strategic Training Program and the Pamela Greenaway-Kohlmeier Translational Breast Cancer Research Unit Seminar Series - Invited Speaker, London ON, November 27, 2008. Presentation "Hereditary diffuse gastric cancer: from the bench through families to the population"
Hereditary Diffuse Gastric Cancer Workshop, International Gastric Cancer Linkage Consortium, Cancer Research UK Cambridge Research Institute, British Society of Gastroenterology, Cambridge, UK, November 20-21, 2008. Presentation
University of British Columbia, Medical Undergraduate Society Research Forum, Vancouver, BC, November 06, 2008. Presentation
Canadian Cancer Research Alliance/International Cancer Genome Consortium, Scientific Workshop, Toronto, ON, October 28, 2008. Presentation on Western Canada's ovarian cancer tumour inventory
American College of Surgeons 94th Annual Clinical Congress, San Francisco, USA, October 14, 2008. Presentation "Hereditary diffuse gastric cancer"
National Cancer Research Institute Cancer Conference, Birmingham, UK, October 05-08, 2008. Presentation "Ovarian carcinoma subtypes are different diseases: lesson from biomarker studies"
Macgregor Lecturer, University of Alberta, Dept of Laboratory Medicine and Pathology, Presentation "From cancer susceptibility to next generation sequencing: the evolving role of oncopathology in the post genomic era: my research in CTC's, ovarian cancer genomics and hereditary cancer in a broader context"
Familial Cancer: Research and Practice: Combined meeting of kConFab, The Australian Ovarian Cancer Study & the Family Cancer Clinics of Australia and New Zealand, Couran Cove Island, AU, August 19-22, 2008. Presentations "Hereditary diffuse gastric cancer and Ovarian carcinoma subtypes are different diseases"
4th PacRim Breast & Prostate Cancer Conference, August 12-16, 2008. Co-Chair of Session "Biomarkers and patient care - will they tell us who, when and how to treat?"
Ovarian Cancer Conference, Rhodes, Greece, June 26-July 01, 2008. Presentation "Ovarian carcinomas are different subtypes: lessons from biomarker studies"
Cancer Research Institute of the University of Montreal, Montreal, QC, May 07, 2008. Seminar "If ovarian cancer subtypes are different diseases, how does this change ovarian cancer research?"
4th Annual Canary Foundation Symposium, Stanford University CA, May 20-22, 2008.
Ovarian Cancer Research Trainee Symposium, Montreal, QC, May 03, 2008. Presentation "Anatomy, cell biology and pathology"
CBCRA Reasons for Hope Conference, Vancouver, BC, April 25-27, 2008. Plenary session "Molecular oncology, the baby and the bathwater: an introduction", Oral Presentation "Carbonic Anhydrase IX (CA IX) is a Predictive Marker for Benefit from Post-mastectomy Adjuvant Locoregional Radiation (RT): Results from the British Columbia Randomized Radiation Trial", and Ask the Experts Breakfast Panel
University of Sherbrooke, Functional Genomics Laboratory, Sherbrooke, QC, April 16, 2008. "Hereditary diffuse gastric cancer: genetics, pathology and clinical management"
Genomics Institute of the Norvatis Research Foundation, Oncology Board Meeting, San Diego, CA, April 09, 2008. "FISH: Search for Translocated Kinases"
"Hereditary diffuse gastric cancer: genetics, pathology and clinical management"
Genetics Rounds, Alberta Children's Hospital, Calgary, AB, January 23, 2008
"Ovarian Carcinomas: different diseases not subtypes - setting the stage to f a new paradigm for ovarian cancer management"
Tom Baker Cancer Centre Grand Rounds, Calgary, AB, January 23, 2008.
7th Annual Scientific Meeting, University of Montreal, Dept. of Medical Genetics, Montreal QC, December 06, 2007. "Hereditary diffuse gastric cancer: genetics, pathology, and clinical management."
BC Cancer Agency Annual Cancer Conference, Presentation "The Centre for Translational and Applied Genomics (CTAG): A molecular pathology platform for clinical development and research." Session chair: Predictive oncology & targeted therapeutics. Westin Bayshore, Vancouver, BC, November 29-December 01, 2007
Toronto Ovarian Cancer Research Network, Princess Margaret Hospital, Toronto ON, November 02, 2007. "Ovarian carcinoma subtypes are different diseases: implications for biomarker studies and management."
Institute of Molecular Pathology and Immunology of the University of Porto, Porto Portugal, October 15-16, 2007. "Hereditary diffuse gastric cancer."
Mount Sinai School of Medicine, New York City, NY, June 12, 2007.
Surgical Grand Rounds, Memorial Sloan-Kettering Cancer Centre, New York City NY, June 11, 2007. "Hereditary diffuse gastric cancer: from genetics to management."
3rd Annual Canary Foundation Symposium, Stanford University CA, May 22-24, 2007.
Toronto Cancer Stem Cell Workshop, April 17-18, 2008.
The Tucson Symposium, Ventana Medical Systems. Tucson AZ. March 6-7, 2007.
Distinguished Guest Speaker, RCPA Pathology Update, Sydney AU, March 03, 2007. "Hereditary diffuse gastric cancer: Pathology, molecular genetics and clinical management."
RCPA Pathology Update 2007, Sydney Convention & Exhibition Centre. Sydney AU. March 3-4, 2007
University of Melbourne, Dept. of Medicine, Royal Melbourne and Western Hospitals, Peter MacCallum Cancer Centre, Melbourne AU, March 01, 2007. "Hereditary diffuse gastric cancer: Pathology, molecular genetics and clinical management."
Familial Cancer Unit, Dept of Genetic Medicine, Women's & Children's Hospital, North Adelaide AU, February 27, 2007. "Making genetic pathology generic: population based assessment of novel cancer biomarkers."
Familial Cancer Unit, Dept of Genetic Medicine, Women's & Children's Hospital, North Adelaide AU, February 26, 2007. "Hereditary diffuse gastric cancer: Pathology, molecular genetics and clinical management."
Women's & Children's Hospital, Familial Cancer Unit, Department of Genetic Medicine, Evening Presentation, North Adelaide. February 27, 2007
Institute of Medical and Veterinary Sciences, Presentation to Clinicians, Pathologists, and Scientists. Adelaide AU. February 26, 2007
Women's & Children's Hospital, Familial Cancer Unit, Department of Genetic Medicine, Grand Rounds, North Adelaide. February 26, 2007
INSIGHT, Laboratory Services in Canada, the Need for Modernization, Latest Initiatives, Best Practices. Vancouver BC. December 5, 2006
Memorial University of Newfoundland, Provincial Medical Genetics Program, Eastern Health, Health Sciences Centre, Grand Rounds. St. John's NFLD. July 14 & 17, 2006
Guy's Hospital, Hedley Atkins Breast Unit, London UK, July 13, 2006
Breakthrough Breast Cancer Research Centre, Institute for Cancer Research, London UK. June 12, 2006
Bradfield Family Reunion. Las Vegas NV. May 26, 2006
Canary Foundation Scientific Advisory Board. San Jose CA. May 23-25, 2006
Novartis Canada, NEOCAN Investigator Meeting, Montreal PQ, May 6, 2006
Harvard Medical School, Dana Farber Cancer Institute, Boston, MA, Grand Rounds "Hereditary diffuse gastric cancer and the tissue array based development of novel IHC and FISH based cancer biomarkers: cancer genetics for individuals, families and populations". Boston MA. March 10, 2006
GUTG Retreat Agenda 2006, Delta Sun Peaks Resort, Sun Peaks, BC "Recent Advances in Basic Research on Prostate Cancer – Fusion of TMPRSS2 and ETS Transcription Factor Genes in CaP". April 6 to 9, 2006
Yale University, Pathology, Grand Rounds, New Haven CT "Hereditary diffuse gastric cancer and the tissue array based assessment of novel IHC and FISH based cancer biomarkers: cancer genetics for individuals, families and populations". March 9, 2006.
Grand Rounds at Stanford, March 2006
BCCA Annual Cancer Conference 2005, Westin Bayshore Hotel, Vancouver "Hereditary Diffuse Gastric Cancer: The Genetic Based Management of an Extreme Risk Family Cancer Syndrome", November 04, 2005.
Provincial Laboratory Coordinating Office, Pan Pacific Hotel, Vancouver "Translating Molecular Science into Improved Healthcare: Balancing Inevitable Hype with Realistic Hope", November 03, 05
Russian Cancer Research Centre, Moscow, Russia "Genetic analysis of tissue microarrays" & "Hereditary gastric cancer", September 28-29, 2005.
kConfab, Couran Cove Island, Australia "The use of tissue microarrays for the validation of putative breast and ovarian cancer biomarkers and the linkage of molecular phenotypes to epidemiological data." & "Hereditary Diffuse Gastric Cancer", August 30-September 03, 2005.
Queensland Institute of Medical Research, Brisbane, Australia "The development, validation and delivery of cancer biomarkers", August 30, 2005.
Meeting with Marsha Rivkin Centre, Seattle, to present findings on the MRC Pilot Study, June 7, 2005.
Dalhousie University, Dalhousie, Halifax. "Bringing cancer genomics to the bedside: A Pathologist's perspective" & "Tissue Microarrays: from biomarker discovery to clinical application", May 17-20, 2005.
MD Anderson, Houston, Texas. "Tissue Microarray: from the mapping of clinical cytogenetic abnormalities through the clinical delivery of breast cancer biomarkers", April 28-29, 2005.
ASIP Annual Meeting, San Deigo. "TMA-based molecular morphology approaches to the study of human mammary carcinoma", April 2-6, 2005.
USCAP Annual Meeting, San Antonio, Texas. "Use of Tissue microarrays for Clinical Assessment of Breast Cancer Biomarkers" & "Hereditary Diffuse Gastric Cancer: Genetics, Pathology and Management". February 26-March 2, 2005.
96th AACR Annual Meeting, Anaheim, California. (Abstract #1619 - EMSY overexpression in human mammary epithelial cells produces a genetically unstable phenotype that mimcs BRCA2 loss) April 16-19, 2005.
University of Calgary: Heriditary Gastric Cancer: Pathology & Laboratory Medicine Rounds, January 13, 2005
University of Calgary. (Grand Rounds) "Tissue Microarrays in Pathology Research", January 13, 2005.
University of Alberta, Alberta. "Hereditary Gastric Cancer". November 11-13, 2004.
UBC & University of Alberta Depts of Obstetrics & Gynecology Conf: Science & Beyond III., Cancer Genetics: A Three Course Meal, Banff, Alta., November 13, 2004
Alberta Cancer Board's Annual Research Meeting, Banff, Alberta. "From gene array to tissue array: Linking markers to clinical outcomes", November o9-10, 2004.
Roy Col Phys & Surg of Can: CSCI Joe Doupe Lecture, Ottawa, September 30,2004
N Am Assoc Central Can Reg Ann Meeting: Linking tissue archives to cancer registries: Salt Lake City, June 8, 2004.
13th Annual Cancer Symposium: Molecular Changes in Gastric Cancer: Seoul, April 2004
American Soc Clin Onc: GI Symposium: Hereditary Gastric Cancer: San Fran, January 2004.
William Anderson lectureship: Tissue Microarray: More than a Biomarker Validation Tool: Toronto September 29, 2003.
2003 Medical Graduates' Society Reunion: How will the human Genome Project effect medical practice: the cancer story: Memorial University of Newfoundland: August 02, 2003.
Cleveland Clinic: Can Tissue Microarrays Salvage Pathology?: Cleveland Ohio: June 16, 2003.
Breast Intergroup Meeting: The BC Breast Cancer TMA Project and NCIC TMA based studies: Chicago, Illinois: June 25, 2003.
International Gastric Cancer Linkage Consortium Meeting: "An update from Canada" Munich, Germany: May 23, 2003
UBC Departments of Surgery Grand Rounds: Bringing Cancer Genomics to the Bedside: December 11, 2002.
BCALP Annual meeting: Cancer Genetics an introduction for pathologists: November. 22, 2002.
DA Boyes Society: Inherited Gynecologic Cancer a Review; Vancouver, November 08, 2002
University of Toronto (Mt. Sinai Hosp): Visiting lectureship in Cancer Genetics, Nov. 25, 2002.
BCCA Annual Research Meeting: Invited lecture (using IHC to Validate Genomic findings), Nov 30, 2002
Pathology Update at Whistler: Cancer Genetics a Three Course Meal: August 07, 2002.
International Gastric Cancer Linkage cocnsortium: New families and an Animal Model for HDGC: Oporto, Portugal, May 27, 2002
GOC Annual meeting: Cancer Genetic Review, April 13, 2002.
NICI Tissue Banking Group: Tissue Microarray Technology, April 14, 2002.
"Early Gastric Cancer, Genetically susceptible individuals".
United States and Canadian Academy of Pathology and Society for Pediatric Pathology, Chicago, Feb. 2002.
BCCA Annual Cancer Research conference; Cell Signaling for Beginners (with G. Krystal), November 2001.
World Cardiovascular Congress: DNA Chips: What Microarrays Can Tell Us. July 09, 2001.
International Gastric Cancer Linkage Consortium Workshop. June 2-3, 2001. Vancouver.
Canadian Association of Pathologists: Testing for Hereditary cancer syndromes: June 15, 2001.
Northwest Radiobiology/Molecular Oncology Review Course. Cancer Genetics Review. May 11, 2001.
BC Surgeons Conference, December 2, 2000
Genetics & Genomic "What you need to know but were not taught". The Annual BC Cancer Agency Clinical Cancer Conference, November 24, 2000
New Century New Diagnostics, UBC 50th Golden Jubilee Conference, November 4, 2000
Hereditary Cancers: Basic review and implications for gynecologic practice, D.A. Boyes Society, November 3, 2000
Hereditary Cancer, UBC 50th Golden Jubilee Conference, November 4, 2000.
Advances in the Genetics of GI Tumors. Pacific Northwest Society of Pathologists meeting, September 15, 2000
Prophylactic Gastrectomy for Cure: International Gastric Cancer Linkage Consortium Meeting, Sienna It, June 3, 2000
Familial Gastric Cancer: Cambridge Conference on Inherited Predisposition to Cancer: April 1999